Kerman University of Medical Sciences

Document Type: Original Article

Author

Saint James School of Medicine, Park Ridge, Illinois, United States of America

Abstract

Background: Synthetic cannabinoid use such as “K2” and “Spice” is popular secondary to its inability to be detected in a urine drug screen. It is associated with a wide range of myocardial pathologies including obstructive and non-obstructive coronary disease such as Takotsubo cardiomyopathy. Case Report: A case report of an emancipated 15-year-old male experiencing Takotsubo cardiomyopathy after using the synthetic cannabinoid “Spice” is presented here. Conclusion: Synthetic cannabinoids act as full agonists and bind to cannabinoid receptors (CB receptors) with a much greater potency compared to natural forms of marijuana. In particular, “Spice” decreases the release of glutamate via the CB receptor type 1 (CB1 receptor) in higher concentrations, which causes mitogen-activated protein kinase (MAPK) activation, substances released in response to stressful environments being experienced in the body. These effects can cause the sympathetic system to become activated by synthetic cannabinoid use, leading to a surge in catecholamines and a change from normal positive inotropy to abnormally-mediated negative inotropy. Use of synthetic cannabinoids can therefore be associated with Takotsubo cardiomyopathy. This case has important implications for additional examination secondary to the sparse information describing co-occurrence of Takotsubo cardiomyopathy and synthetic cannabinoid use.

Keywords

Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci 2015; 350(1): 59-62.
2. Fattore L, Fratta W. Beyond THC: The new generation of cannabinoid designer drugs. Front Behav Neurosci 2011; 5: 60.
3. Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, et al. Crystal structure of the human cannabinoid receptor CB1. Cell 2016; 167(3): 750-62.
4. Cooper ZD. Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Curr Psychiatry Rep 2016; 18(5): 52.
5. Gudsoorkar VS, Perez JA. A new differential diagnosis: synthetic cannabinoids-associated acute
renal failure. Methodist Debakey Cardiovasc J 2015; 11(3): 189-91.
6. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, et al. Clinical features and outcomes of Takotsubo (Stress) cardiomyopathy. N Engl J Med 2015; 373(10): 929-38.
7. Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, et al. Transient left ventricular apical ballooning without coronary artery stenosis: A novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol 2001; 38(1): 11-8.
Proof Version
Drug-induced Takotsubo Cardiomyopathy Mohammed.
Addict Health, Summer 2019; Vol 11, No 3 205
http://ahj.kmu.ac.ir, 06 July
8. Paur H, Wright PT, Sikkel MB, Tranter MH, Mansfield C, O'Gara P, et al. High levels of circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent manner: A new model of Takotsubo cardiomyopathy. Circulation 2012; 126(6): 697-706.
9. Ramshini E, Dabiri S, Arjmand S, Sepehri G, Khaksari M, Ahmadi-Zeidabadi M, et al. Attenuation effect of cannabinoid type 1 receptor activation on methamphetamine-induced neurodegeneration and locomotion impairments among male rats. Addict Health 2017; 9(4): 206-13.
10. Rajesh M, Batkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horvath B, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 2012; 61(3): 716-27.
11. Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, et al. Isolation and pharmacological evaluation of minor cannabinoids
from high-potency Cannabis sativa. J Nat Prod 2015; 78(6): 1271-6.
12. Batkai S, Pacher P. Endocannabinoids and cardiac contractile function: Pathophysiological implications. Pharmacol Res 2009; 60(2): 99-106.
13. Pacher P. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: New hopes, old concerns? Arterioscler Thromb Vasc Biol 2009; 29(1): 7-9.
14. Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: The good, the bad, and the ugly. Nat Rev Cardiol 2018; 15(3): 151-66.
15. Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: A systematic review. Eur Heart J 2006; 27(13): 1523-9.
16. Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM. Catecholamine-induced cardiomyopathy. Endocr Pract 2008; 14(9): 1137-49.